1. Home
  2. JAZZ vs BIO Comparison

JAZZ vs BIO Comparison

Compare JAZZ & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAZZ
  • BIO
  • Stock Information
  • Founded
  • JAZZ 2003
  • BIO 1952
  • Country
  • JAZZ Ireland
  • BIO United States
  • Employees
  • JAZZ N/A
  • BIO N/A
  • Industry
  • JAZZ Biotechnology: Pharmaceutical Preparations
  • BIO Biotechnology: Laboratory Analytical Instruments
  • Sector
  • JAZZ Health Care
  • BIO Industrials
  • Exchange
  • JAZZ Nasdaq
  • BIO Nasdaq
  • Market Cap
  • JAZZ 6.1B
  • BIO 6.7B
  • IPO Year
  • JAZZ 2007
  • BIO N/A
  • Fundamental
  • Price
  • JAZZ $97.78
  • BIO $239.02
  • Analyst Decision
  • JAZZ Strong Buy
  • BIO Strong Buy
  • Analyst Count
  • JAZZ 13
  • BIO 4
  • Target Price
  • JAZZ $181.85
  • BIO $330.50
  • AVG Volume (30 Days)
  • JAZZ 1.3M
  • BIO 314.3K
  • Earning Date
  • JAZZ 05-06-2025
  • BIO 05-01-2025
  • Dividend Yield
  • JAZZ N/A
  • BIO N/A
  • EPS Growth
  • JAZZ 49.21
  • BIO N/A
  • EPS
  • JAZZ 7.51
  • BIO N/A
  • Revenue
  • JAZZ $4,064,808,000.00
  • BIO $2,541,100,000.00
  • Revenue This Year
  • JAZZ $7.60
  • BIO $0.84
  • Revenue Next Year
  • JAZZ $3.47
  • BIO $4.64
  • P/E Ratio
  • JAZZ $13.00
  • BIO N/A
  • Revenue Growth
  • JAZZ 5.76
  • BIO N/A
  • 52 Week Low
  • JAZZ $95.49
  • BIO $215.38
  • 52 Week High
  • JAZZ $148.06
  • BIO $387.99
  • Technical
  • Relative Strength Index (RSI)
  • JAZZ 33.01
  • BIO 47.23
  • Support Level
  • JAZZ $97.50
  • BIO $228.91
  • Resistance Level
  • JAZZ $120.67
  • BIO $243.75
  • Average True Range (ATR)
  • JAZZ 4.33
  • BIO 9.67
  • MACD
  • JAZZ -0.53
  • BIO 0.36
  • Stochastic Oscillator
  • JAZZ 1.21
  • BIO 32.51

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: